LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Vertex Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

390.79 -0.38

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

390

Макс.

391.16

Ключевые показатели

By Trading Economics

Доход

387M

1B

Продажи

195M

3B

P/E

Средняя по отрасли

27.643

35.724

Прибыль на акцию

4.06

Рентабельность продаж

34.84

Сотрудники

6,100

EBITDA

641M

1.4B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+25.25% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

3 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-22B

100B

Предыдущая цена открытия

391.17

Предыдущая цена закрытия

390.79

Новостные настроения

By Acuity

10%

90%

9 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 авг. 2025 г., 00:05 UTC

Популярные акции

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 авг. 2025 г., 21:21 UTC

Отчет
Главные движущие силы рынка

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 авг. 2025 г., 20:45 UTC

Отчет

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

5 мая 2025 г., 21:00 UTC

Отчет

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

5 авг. 2025 г., 20:44 UTC

Отчет

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 авг. 2025 г., 18:17 UTC

Отчет

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 авг. 2025 г., 15:25 UTC

Отчет

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 авг. 2025 г., 14:12 UTC

Отчет

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 авг. 2025 г., 11:27 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:55 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:36 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:18 UTC

Отчет

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

4 авг. 2025 г., 20:15 UTC

Отчет

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 авг. 2025 г., 20:14 UTC

Отчет

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 авг. 2025 г., 20:14 UTC

Отчет

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 авг. 2025 г., 20:14 UTC

Отчет

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 авг. 2025 г., 20:13 UTC

Отчет

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 авг. 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 авг. 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 авг. 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 авг. 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

6 мая 2025 г., 16:31 UTC

Отчет

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5 мая 2025 г., 20:03 UTC

Отчет

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27 апр. 2025 г., 11:00 UTC

Главные новости

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11 апр. 2025 г., 09:30 UTC

Главные новости

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28 февр. 2025 г., 12:00 UTC

Главные новости

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Сравнение c конкурентами

Изменение цены

Vertex Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

25.25% рост

Прогноз на 12 месяцев

Средняя 489.76 USD  25.25%

Максимум 624 USD

Минимум 405 USD

Основано на мнении 25 аналитиков Wall Street, спрогнозировавших целевые цены для Vertex Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

25 ratings

15

Покупка

10

Удержание

0

Продажа

Техническая оценка

By Trading Central

428.545 / 498.65Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Weak Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

9 / 371Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.